Mast cells are primary effectors in allergic reactions, and may have important roles in disease by secreting histamine and various inflammatory and immunomodulatory substances 1, 2 . Although they are classically activated by immunoglobulin (Ig)E antibodies, a unique property of mast cells is their antibody-independent responsiveness to a range of cationic substances, collectively called basic secretagogues, including inflammatory peptides and drugs associated with allergic-type reactions 1, 3 . The pathogenic roles of these substances have prompted a decades-long search for their receptor(s). Here we report that basic secretagogues activate mouse mast cells in vitro and in vivo through a single receptor, Mrgprb2, the orthologue of the human G-protein-coupled receptor MRGPRX2. Secretagogueinduced histamine release, inflammation and airway contraction are abolished in Mrgprb2-null mutant mice. Furthermore, we show that most classes of US Food and Drug Administration (FDA)-approved peptidergic drugs associated with allergic-type injection-site reactions also activate Mrgprb2 and MRGPRX2, and that injection-site inflammation is absent in mutant mice. Finally, we determine that Mrgprb2 and MRGPRX2 are targets of many small-molecule drugs associated with systemic pseudo-allergic, or anaphylactoid, reactions;
we show that drug-induced symptoms of anaphylactoid responses are significantly reduced in knockout mice; and we identify a common chemical motif in several of these molecules that may help predict side effects of other compounds. These discoveries introduce a mouse model to study mast cell activation by basic secretagogues and identify MRGPRX2 as a potential therapeutic target to reduce a subset of drug-induced adverse effects.
Responsiveness to basic secretagogues is conserved among mammals 4 and is also found in birds 5 , indicating an ancient, fundamental role for its mechanism. Many basic secretagogues are endogenous peptides, often linked to inflammation; however, they activate connective tissue mast cells only at high concentrations and independent of their canonical receptors, so another mechanism of stimulation must exist 6 . Several candidate proteins that bind polycationic compounds have been proposed as basic secretagogue receptors [6] [7] [8] [9] . Among these, MRGPRX2 has been screened with the most compounds 8, [10] [11] [12] [13] [14] , and short interfering RNA (siRNA) knockdown studies support at least a partial role for MRGPRX2 in activation by four non-canonical basic secretagogues 11, 13 . However, no direct in vivo study or knockout model has been employed for any candidate. The investigation of MRGPRX2 in mice is complicated because 1 The Solomon H. Snyder Department of Neuroscience, Department of Neurosurgery, Center for Sensory Biology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, USA. 2 Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada. 3 Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21205, USA. 4 National Institute for Nanotechnology, National Research Council Canada, Edmonton, Alberta T6G 2M9, Canada. 5 Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA. the gene cluster containing the four human MRGPRX members is dramatically expanded in mice, consisting of 22 potential coding genes, many with comparable sequence identity to MRGPRX2 (Fig. 1a ). Therefore, a mouse MRGPRX2 orthologue must be determined by expression pattern and pharmacology. A stringent polymerase chain reaction with reverse transcription (RT-PCR) screen in mouse primary mast cells uncovered a band for a single family member, Mrgprb2 (Fig. 1b ), whereas MRGPRX1 orthologues were not expressed at relevant levels (Extended Data Fig. 1a, b ). Functionally, HEK293 cells heterologously expressing mouse Mrgprb2 (Mrgprb2-HEK) responded to the MRGPRX2 agonist proadrenomedullin amino-terminal 20 peptide, fragment 9-20 (PAMP(9-20)) 14 ( Fig. 1c ) and compound 48/80 (48/80), a classical mast cell activator and canonical basic secretagogue (Extended Data Fig. 2 ). Mrgprb2-HEK cells also responded to other MRGPRX2 ligands, including the basic secretagogue Substance P, but had no response to the MRGPRX1 ligand chloroquine 15 ; no closely related family members in mice responded to any compound (Extended Data Figs 1c and 2a, c).
To determine the expression of Mrgprb2, we generated Mrgprb2 bacterial artificial chromosome (BAC) transgenic mice in which the expression of eGFP-Cre recombinase was under the control of the Mrgprb2 promoter. Strikingly, Cre expression patterns indicate that Mrgprb2 expression is highly specific to connective tissue mast cells ( Fig. 1d and Extended Data Figs 3, 4) . Together, the pharmacological and expression data indicate that Mrgprb2 is the mouse orthologue of human MRGPRX2. Next, we determined whether Mrgprb2 is the basic secretagogue receptor in mouse mast cells. The Mrgprb2 genomic locus contains too much repetitive sequence to permit gene targeting through homologous recombination (Extended Data Fig. 5a ). Therefore, we used a zinc-fingernuclease-based strategy to generate a mouse line with a 4 base pair (bp) deletion in the Mrgprb2 coding region (Mrgprb2 MUT mice), resulting in a frameshift mutation and early termination shortly after the first transmembrane domain (Extended Data Fig. 5b-d ). The mutation was stable and inheritable (Extended Data Fig. 5c ), so we regard Mrgprb2 MUT as a functional null. Mast cell numbers were comparable in tissues of wild-type and Mrgprb2 MUT mice, indicating that Mrgprb2 is not essential for mast cell survival or targeting to tissue (Extended Data Fig. 6a ). The responsiveness of peritoneal mast cells to anti-IgE antibodies ( Fig. 2a ) and endothelin (Extended Data Fig. 7 ) was also comparable, demonstrating that Mrgprb2 mutation does not globally impair IgE or G-proteincoupled receptor (GPCR)-mediated mast cell signalling. However, 48/ 80-induced mast cell activation ( Fig. 2a ) and tissue histamine release were essentially abolished in mutant mast cells ( Fig. 2b and Extended Data Fig. 6b ). Furthermore, we found that 48/80-evoked tracheal contraction ( Fig. 2c ) and hindpaw inflammation (extravasation and swelling; Fig. 2d ) were almost completely absent in an Mrgprb2 MUT background, while antigen ( Fig. 2c ) and anti-IgE evoked responses (Extended Data Fig. 8 ) were comparable to wild-type mice. Finally, we found that four additional basic secretagogues, as well as the MRGPRX2 agonists PAMP(9-20) and cortistatin 10 , strongly activated wild-type but not Mrgprb2 MUT mast cells ( Fig. 2e and Extended Data Fig. 9a ). HEK293 cells expressing Mrgprb2 or MRGPRX2 (MRGPRX2-HEK) also responded to these secretagogues (Extended Data Fig. 2 ). Taken together, we conclude that Mrgprb2 is the mouse mast cell basic secretagogue receptor. It is likely that the list of small, basic peptides that activate Mrgprb2 is greater than the number in this study; indeed, dozens of such peptides have been shown to activate mast cells 3, 6, 16, 17 . Notably, human MRGPRX2 is much more sensitive to substance P than mouse Mrgprb2 (Extended Data Fig. 2c ), suggesting a potential species-specific role for substance P in mast cell signalling.
We next considered whether Mrgprb2 factors in allergic-type reactions. We specifically addressed drug-induced reactions because many therapeutic drugs are cationic. Up to 15% of drug-induced adverse reactions appear to be allergic in nature; however, many do not correlate well with IgE antibody titre, indicating that antibody-independent, or pseudoallergic, mechanisms participate 18 . We focused first on peptidergic drugs Anti-IgE responses were not significantly different. Scale bar, 10 mm. b, Histamine release into the supernatant from trachea and abdominal skin from wild-type and Mrgprb2 MUT mice after exposure to 48/80 (30 mg ml 21 ) for 30 min at 37 uC. n 5 5 for trachea, n 5 8 for skin. c, Top, representative traces showing contractions of trachea isolated from wild-type and Mrgprb2 MUT mice (previously sensitized to ovalbumin (Ova)) in response to 48/80 (30 mg ml 21 ) or ovalbumin (10 mg ml 21 ; that is, IgE dependent). Bottom, average data; maximum total contraction determined as response to 10 mM carbamycholine added at the end of the experiment. n 5 5 for 48/80 wild type, 
RESEARCH LETTER
because most are introduced subcutaneously or intramuscularly at millimolar concentrations (Supplementary Information), high enough for cationic peptides to activate mast cells. The most frequent allergic-type response described in the FDA labels of these drugs is an injection-site reaction (ISR), a local swelling and/or flare of variable size that can be accompanied by pain or pruritus. In a survey of FDA-approved peptidergic drugs, we found that the vast majority associated with ISRs are cationic (Supplementary Information). We found that representative members of all common, commercially available classes of these cationic drugs activated mast cells in an Mrgprb2-dependent manner, whereas the innocuous protein insulin had no effect ( Fig. 3a and Extended Data Fig. 9b, c) . Consistently, all of these peptides except insulin activate both Mrgprb2-HEK and MRGPRX2-HEK cells (Extended Data Fig. 2 ). We selected the drug icatibant for further study because it induces ISRs in nearly every patient 19 . Icatibant at the clinical concentration induced extensive extravasation and swelling, similar to human ISRs, in wildtype mice but not in Mrgprb2 MUT mice (Fig. 3b ). Mice pretreated with the mast cell stabilizer ketotifen also showed no inflammation (without ketotifen: 40.7 6 2.1% increase in paw thickness; with ketotifen: 3.1 6 0.6% increase; n 5 4 each; P 5 2.2 3 10 26 ), strongly indicating that mast cells mediated the inflammation. Furthermore, icatibant (as well as positive controls 48/80 and mastoparan) induced histamine release from wild-type peritoneal mast cells, whereas Mrgprb2 MUT mast cells released substantially less histamine ( Fig. 3c ). However, IgE-mediated histamine release was unaffected by Mrgprb2 deletion (Fig. 3c ). These data lead us to anticipate that drug-induced ISRs may be alleviated by targeting MRGPRX2 or by using peptides with less potent MRGPRX2 agonist properties. Next, we explored the possibility that Mrgprb2 mediates pseudoallergic reactions induced by small molecules. We focused on intravenous drugs because they are often administered rapidly and in high doses, and thus are more likely to achieve high blood concentrations and rapid tissue distribution than drugs administered through other routes. Symptoms of pseudo-allergic reactions after intravenous administration, which at their most severe are called anaphylactoid, include skin flushing or rash, changes in blood pressure or heart rate, and bronchospasms 20 . We based our initial search on the structure of 48/80. While the structurefunction relationship of 48/80 as an MRGPRX2 agonist is unknown, a cyclized variant containing a tetrahydroisoquinoline (THIQ) motif ( Fig. 4a ) is reported to be seven times more potent than 48/80 as a mast cell degranulator 21 . A search of FDA-approved drugs containing a THIQ recovered members of the nicotinic receptor antagonist non-steroidal neuromuscular blocking drugs (NMBDs), including tubocurarine and atracurium (Fig. 4b) . NMBDs are used routinely in surgery to reduce unwanted muscle movement and allow intratracheal intubation for mechanical ventilation. Intriguingly, NMBDs alone are responsible for nearly 60% of allergic reactions in a surgical setting 22 , and all except succinylcholine induce histamine release in humans 23 . We found that members of all NMBD families (Supplementary Information) except succinylcholine activated mast cells in an Mrgprb2-dependent manner at concentrations as low as 0.5% of the clinical injection concentration ( Fig. 4c and Extended Data Fig. 9d ). Interestingly, rocuronium does not contain a THIQ but has a bulky hydrophobic group with a charged nitrogen within several angstroms ( Fig. 4b ), reminiscent of 48/80. Therefore, we searched using modifications of the THIQ motif and the 48/80 structure, including changes in cyclization and position of the positive or polar nitrogen, limiting our assay to intravenous drugs at high injection concentrations. We identified the fluoroquinolone family of antibiotics as having a similar motif ( Fig. 4d ). Like NMBDs, these are associated with allergic-type reactions 24,25 and can activate mast cells 26, 27 . We found that the four members approved for intravenous use activated Mrgprb2-HEK and MRGPRX2-HEK cells (Extended Data Fig. 2 ), and 
LETTER RESEARCH
mast cells in an Mrgprb2-dependent manner ( Fig. 4e and Extended Data Fig. 9e ). Correspondingly, atracurium and ciprofloxacin induced histamine release in wild-type peritoneal mast cells and substantially less so in Mrgprb2 MUT mast cells ( Fig. 3c ). We selected ciprofloxacin for in vivo tests of anaphylaxis, which in mice is measured most often by a drop in body temperature, probably due to changes in blood pressure and peripheral vasodilation 28 . Rodents are nearly immune to histamine toxicity at a systemic level, contrary to other experimental organisms 4 , but can be rendered sensitive to mast cell activators and secreted products by pretreatment with b-adrenergic blockers 29, 30 . Under these conditions, a high dose of ciprofloxacin induced a rapid drop in body temperature that was very slow to recover, while Mrgprb2 MUT mice showed a much smaller drop that recovered quickly (Fig. 4f) . These results establish that mast cell activation through Mrgprb2 is an off-target effect of fluoroquinolones and other drugs. Finally, we determined whether drugs associated with pseudo-allergies activate human mast cells through MRGPRX2. We found that representative members of each examined drug class evoked release of histamine, tumour necrosis factor (TNF), prostaglandin D 2 (PGD 2 ) and b-hexosaminidase from LAD2 cells (Extended Data Fig. 10a ). 48/80 and mastoparan were used as positive controls. Importantly, MRGPRX2-siRNA-treated LAD2 cells exhibited significantly less b-hexosaminidase release evoked by these substances compared with responses in control-siRNA-treated cells, while IgE-mediated release was comparable (Extended Data Fig. 10b ). The residual b-hexosaminidase release observed in MRGPRX2-siRNA-treated cells is probably due to incomplete messenger RNA and/or protein knockdown.
Knowledge of the role of MRGPRX2 in drug-induced pseudo-allergies should expand further, for two reasons. First, ligand binding requirement studies should enable more specific screens for drugs that crossactivate MRGPRX2. Second, screening orally administered drugs may uncover more MRGPRX2 ligands, since common side effects of orally administered drugs include gastrointestinal problems and headache, both of which may have a mast cell component.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Information is available in the online version of the paper.
METHODS
Animal models. All experiments were performed in accordance with a protocol approved by the Animal Care and Use Committee at the Johns Hopkins University School of Medicine. All experiments involving equal treatments in wild-type and mutant samples and animals were conducted by experimenters blind to conditions. Analysis. Group data were expressed as mean 6 s.e.m. Two-tailed unpaired Student's t-test was used to determine significance in statistical comparisons, and differences were considered significant at P , 0.05. Statistical power analysis was used to justify the sample size. We assumed the data were normally distributed since the most outcome values were symmetrically distributed around the mean value within each group. The variance is similar between groups as determined by the F test. Mast cells deemed to be damaged, either by visible lack of fibronectin adherence or by abnormally high resting calcium levels, were excluded from analysis. Otherwise, no samples or animals subjected to successful procedures and/or treatments were excluded from the analysis. No randomization was used for animal studies since it is not applicable for the studies. Peptides and drugs. Compound 48/80, vespid mastoparan, rocuronium, tubocurarine, ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin were from Sigma. Cortistatin was from Tocris Biosciences. PAMP (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) was custom synthesized and purified to $98% by Genscript. Leuprolide was from Genscript. Substance P, kallidin, mastoparan, cetrorelix, octreotide, sermorelin (growth hormone releasing factor 1-29) and icatibant (HOE-140) were from Anaspec. Atracurium and mivacurium were from Santa Cruz Biotechnology. Recombinant human insulin was from Roche. Goat anti-mouse IgE (Ab9162) was from Abcam. Drug preparation and storage. Atracurium, mivacurium, tubocurarine and all fluoroquinolone solutions were prepared on the day of the experiment because the potencies of the first three were found to be susceptible to oxidation and/or freezethaw effects, while the solubility of the fluoroquinolones was best when prepared fresh. Propranolol was also prepared fresh on the day of the experiment to minimize the chances of a loss in potency. All fluoroquinolones except levofloxacin were dissolved into CIB adjusted to pH 3.5. All other drugs were prepared as 1003-1,0003 aliquots and stored at 280 uC before thawing at 4 uC and diluting into calcium imaging buffer or saline.
Mrgpr RT-PCR screen. RNA was purified from 4 3 10 4 mouse peritoneal mast cells with a Qiagen RNEasy Micro column, according to the manufacturer's suggestions. RNA was treated for 20 min with DNase I (New England BioLabs) and re-purified on another RNEasy Micro column. Eight nanograms of RNA was used to generate first-strand complementary DNA using a SuperScript III kit (Invitrogen) according to the manufacturer's instructions, using oligo dT primers and scaling the recommended 10 ml reaction up to 60 ml. The negative control reaction was the same except that SuperScript III reverse transcriptase was replaced by water. Twentyfive microlitre PCR reactions were run with 12.5 ml RedTaq ReadyMix (Sigma), 0.5 ml dimethylsulphoxide (DMSO), 0.25 ml each of 50 mM gene-specific forward and reverse primers, 10 ml water and 2 ml mixture from the cDNA or negative control synthesis reactions. All reactions used a 4 min initial step at 95 uC, 30 s annealing at specific temperatures (described later), 40 s extension at 72 uC, and 25 s at 95 uC (with the last three steps repeated 39 times), and a final 4 min step at 72 uC. Expression constructs. Mrgpr genes were cloned and inserted into the pcDNA3.1 mammalian expression plasmid using standard techniques. All mouse genes had a Kozak sequence at their amino terminus and also encoded a carboxy-terminal Flag tag separated from the genes by the amino acid linker DIIL. cDNA constructs. First-strand cDNA was prepared as described for RT-PCR screens, and amplification was performed using the Q5 HotStart High Fidelity Master Mix (New England Biolabs). At least five different clones each prepared from wildtype and mutant mice were sequenced to verify the presence of the deletion in the mutant and the absence of any other mutation from wild type or mutant. Calcium imaging in HEK293 cells. In initial screens, HEK293 cells (not tested for mycoplasma but rapidly dividing) were transiently transfected with gene constructs including a C-terminal Flag tag, and plated on 100 mg ml 21 poly-D-lysine-coated glass coverslips 6 h after transfection. Twenty-four hours later, cells were loaded with AM esters of the calcium indicators Fura-2 or Fluo-4 (Molecular Probes) along with 0.02% Pluronic F-127 (Molecular Probes) for 45 min at 37 uC. Fura-2loaded cells were imaged during 340 and 380 nm excitation, and Fluo-4 loaded cells were imaged during 488 nm excitation. Later experiments used cell lines stably expressing receptors along with transient or stable expression of the promiscuous G protein Ga15. Cells were imaged in calcium imaging buffer (CIB; NaCl 125 mM, KCl 3 mM, CaCl 2 2.5 mM, MgCl 2 0.6 mM, HEPES 10 mM, glucose 20 mM, NaHCO 3 1.2 mM, sucrose 20 mM, brought to pH 7.4 with NaOH). Unless otherwise specified, drugs were perfused into the chamber for 45 to 60 s and responses were monitored at 5-s intervals for an additional 60-90 s. EC 50 determination. HEK293 cells stably expressing Ga15 and either Mrgprb2 or MRGPRX2 were plated at 4 3 10 4 cells per well in 96-well plates and incubated overnight. The next day, media was removed and replaced with imaging solution from the FLIPR Calcium 5 assay kit (Molecular Devices), diluted according to manufacturer's suggestions in Hank's balanced salt solution (HBSS) with 20 mM HEPES, pH 7.4. Cells were incubated in 100 ml imaging solution at 37 uC for 60 min, and allowed to recover for 15 min at room temperature before imaging in a Flexstation 3 (Molecular Devices). Wells were imaged according to manufacturer's specifications for 120 s, with 50 ml of test substances at three times the concentration added 30 s after imaging began. Responses were determined by subtracting the minimum signal from the maximum signal. Substances were tested in duplicate wells, the signals were averaged, and EC 50 values were determined for each trial by normalizing to the peak response to the substance in that trial. All drugs were dissolved in HBSS plus HEPES solution, with the following exceptions due to solubility issues: cetrorelix acetate was dissolved in saline containing 2.5 mM CaCl 2 and 0.6 mM MgCl 2 , and fluoroquinolones except ofloxacin were dissolved in the same solution except that the pH was adjusted with HCl to 3.5; ofloxacin required 100 mg ml 21 of lactic acid for full solubility. We also noticed that peptides sometimes lost potency after a freeze-thaw cycle, so most peptides were prepared directly from lyophilized stock. Peritoneal mast cell purification and imaging. Adult male and female mice 2-5 months of age were killed through CO 2 inhalation. A total of 12 ml of ice-cold mast cell dissociation media (MCDM; HBSS with 3% fetal bovine serum and 10 mM HEPES, pH 7.2) were used to make two sequential peritoneal lavages, which were combined and cells were spun down at 200g. The pellet from each mouse was resuspended in 2 ml MCDM, layered over 4 ml of an isotonic 70% Percoll suspension (2.8 ml Percoll, 320 ml 103 HBSS, 40 ml 1 M HEPES, 830 ml MCDM), and spun down for 20 min, 500g, 4 uC. Mast cells were recovered in the pellet. Purity was .95%, as assayed by avidin staining and by morphology. Mast cells were resuspended at 5 3 10 5 -1 3 10 6 cells ml 21 in DMEM with 10% fetal bovine serum and 25 ng ml 21 recombinant mouse stem cell factor (Sigma), and plated onto glass coverslips coated with 30 mg ml 21 fibronectin (Sigma). For counting, instead of plating, suspended mast cells were diluted 1/10 and affixed to slides by spinning at 1,000 r.p.m. for 5 min at 4 uC on a CytoSpin (Thermo Scientific). For imaging, after 2 h of incubation at 37 uC, 5% CO 2 , mast cells were loaded with Fluo-4 along with 0.02% Pluronic F-127 for 30 min at room temperature, washed three times in CIB and used immediately for imaging. Cells were used within 2 h of loading. Cells were identified as responding if the [Ca 21 ] i rose by at least 50% for at least 10 s, which clearly distinguishes a ligand-induced response from random flickering events. Average traces were calculated by taking the average response from each cell in a mouse, and averaging those. BAC transgenic mice generation. We purchased the BAC clone RP23-65I23 from the Children's Hospital Oakland Research Institute. This clone contains the Mrgprb2 RESEARCH LETTER locus, ,60 kb of 59 genomic sequence and over 100 kb of 39 genomic sequence. Recombineering in bacteria was used to introduce eGFP-Cre and a polyA signal immediately after the Mrgprb2 start codon 31 . The BAC was linearized with NotI (New England Biolabs) and injected into pronuclei from single-cell-fertilized C57BL/6 eggs. Eggs were implanted into pseudopregnant females. Three BAC mouse lines were established. Although mice were already in a C57BL/6 background, they were crossed for at least four generations to wild-type and tdTomato reporter mice in the C57BL/6 background before use in experiments. BAC mice were mated to ROSA26 tdTomato mice purchased from Jackson Laboratories for imaging studies. Experiments for Fig. 1 used mice homozygous for ROSA26 tdTomato because the tdTomato signal was often heterogeneous and weak in heterozygous mice. Genotyping reactions for BAC mice were run at 61 uC annealing, and primers were: forward, TATATCATGGCCGACAAGCA; reverse, CAGACCGCGCGCCTGA AGA. Both primers are in the eGFP-Cre reading frame but the entire gene and correct placement in the Mrgprb2 locus was verified by previous sequencing. Mrgprb2 mutant mice generation. mRNAs encoding zinc finger nucleases targeting Mrgprb2 were purchased from Sigma. The binding sites were GTTCCTGGGC ATCCG and TGCACACGAATGCCTTCACTG, corresponding to bases 180-194 and 196-216, respectively, of the Mrgprb2 open reading frame. mRNA was diluted to 2 ng ml 21 in 1 mm Tris-HCl buffer, pH 7.4, with 0.25 mm EDTA, and injected into the pronuclei of single-cell-fertilized eggs in the C57BL/6 strain. No overt signs of toxicity were observed. Embryos were implanted into pseudopregnant females. DNA flanking the binding sites was amplified from founder mice and screened for mutations using the Cel-1 assay kit (Transgenomics), according to the manufacturer's suggestions. Three of the first 28 mice were identified and confirmed by DNA sequencing to carry small mutations, and no more screening was performed. In addition to the 4 bp mutation used in this study, a mouse carrying a 1 bp deletion and another with a 2 bp deletion were identified. Wild-type and Mrgprb2 MUT mouse genotyping. Primers used for wild-type mice were GGTTCCTGGGCATCCGTAT and GGTTCCTGGGCATCCGTAT, and reactions were run at an annealing temperature of 62.8 uC. Primers for Mrgprb2 MUT mice were GTTCCTGGGCATCCGCAC and CTTCCGCCTGAACCTTCGGT, and reactions were run at 64.0 uC annealing temperature. Avidin labelling of tissue. Adult male and female mice up to 8 months of age were anaesthetized with pentobarbital and perfused with 20 ml 0.1 M PBS (pH 7.4, 4 uC) followed by 25 ml of fixative (4% formaldehyde (vol/vol), 4 uC). Heart, trachea and skin sections were dissected from the perfused mice. Tissues were post-fixed in fixative at 4 uC overnight. When skin sections were the only tissues needed, they were dissected and placed in fixative directly after asphyxiation of mice by CO 2 inhalation, eliminating the perfusion step. Tissues were cryoprotected in 20% sucrose (wt/vol) for more than 24 h and were sectioned (20 mm width) with a cryostat. The sections on slides were dried at 37 uC for 30 min, and fixed with 4% paraformaldehyde at 21-23 uC for 10 min. The slides were pre-incubated in blocking solution (10% normal goat serum (vol/vol), 0.2% Triton X-100 (vol/vol) in PBS, pH 7.4) for 1 or 2 h at 21-23 uC, then incubated with 1/500 FITC-avidin (Sigma) or rhodamineavidin (Vector Labs) for 45 min. Sections were washed three times with water or PBS and a drop of Fluoromount G (SouthernBiotech) was added before coverslips were placed on top. Heart mast cells were examined near cavities because the density was much higher than elsewhere in the tissue; avidin-positive, tdTomato-negative cells were observed embedded in muscle tissue in very low numbers, but their identity was unclear.
For avidin labelling of peritoneal mast cells, cells were plated as described earlier, fixed with 4% paraformaldehyde at 21-23 uC for 10 min, incubated with 1/1,000 avidin in PBS for 30 min at 21-23 uC, and washed with PBS before immediate imaging. Stomach section immunocytochemistry. Adult male and female mice up to 8 months of age were anaesthetized with pentobarbital and perfused with 20 ml 0.1 M PBS (pH 7.4, 4 uC) followed by 25 ml of fixative (4% formaldehyde (vol/vol), 4 uC). Stomach sections were removed, washed thoroughly, postfixed in 4% formaldehyde for 2 h, and prepared for sectioning by incubation in a 30% sucrose solution for 48 h. Tissue samples were mounted in cryoembedding media and frozen, and 14 mm sections were made using a crytostat and then fixed onto slides. Slides were washed with a 0.2% Triton X-100 PBS solution, incubated for 1 h in a 10% normal goat serum solution, and then incubated overnight at 4 uC with a 1:20 dilution of rat monoclonal anti-mouse MCPT1 (monoclonal antibody RF6.1, eBiosciences) in a 0.2% Triton/1% normal goat serum solution. Slides were washed with the 0.2% Triton solution and incubated for 2 h at room temperature in Triton solution with a 1:500 dilution of a goat anti-rat IgG Alexa Fluor 488 conjugated antibody (Life Technologies). Slides were washed in PBS before coverslips were added with an anti-fade solution for imaging. Peripheral white blood cell preparation. Blood was collected from Mrgprb2-tdTomato mice via cardiac punctures with a syringe containing PBS with 30 units ml 21 heparin and 5 mM EDTA, diluted 1:1 with the same solution, and allowed to cool to room temperature before layering over 6 ml of a Histopaque-1119 solution in a 15 ml conical tube. Tubes were centrifuged at 700g for 30 min, and white blood cells were collected at the interface between the PBS and Histopaque solutions. Cells were washed with PBS and spun down at 500g for 10 min a total of three times. Cells were spun onto poly-lysine-coated slides in a Cytospin 4 (Thermo Scientific) at 600 r.p.m. for 3-5 min, dried overnight on a 37 uC heating block, and incubated for 2 min with Hoechst 33342 diluted to 0.5 mg ml 21 in PBS before coverslip mounting with an anti-fade solution. In parallel, we also stained cells in suspension with Hoechst 33342, spun the cells down, and mixed the resuspended cells directly in a PBS/anti-fade solution before placing directly onto slides and mounting coverslips on the suspension. No tdTomato-positive cells were seen in any preparation using either method. Tissue histamine release studies. Whole tracheae or segments of skin isolated from the abdominal aspect of shaved male and female mice up to 6 months of age (4-8 mg wet weight) were dissected and cleaned of connective tissue. After a 60 min incubation period in oxygenated Krebs' bicarbonate buffer solution (37 uC), the tissue was treated with either vehicle or compound 48/80 for 30 min. The supernatant solution was saved for histamine analysis. The tissue was then subjected to 8% percholoric acid in a 37 uC water bath for 15 min to obtain total histamine content. Histamine was assayed by the automated fluorometric technique previously described 32 . Tracheal contractions. Tracheal contractions were carried out as previously described 33 . For allergen (ovalbumin) responses, mice were actively sensitized by injecting 0.2 ml of an ovalbumin solution (3.75 mg ml 21 ) mixed with Al(OH) 3 three times at an interval of 2 days. Experiments were conducted on male and female animals 8-12 weeks of age beginning 2 weeks after the first injection. Trachea were cleaned of connective tissue and tracheal rings (whole or laterally divided in half), were suspended between two tungsten stirrups in 10 ml organ chambers filled with Krebs' buffer that was warmed to 37 uC and bubbled with 95% O 2 -5% CO 2 to maintain a pH of 7.4. One stirrup was connected to a strain gauge (model FT03; Grass Instruments), and tension was recorded on a Grass Model 7 polygraph (Grass Instruments). Preparations were stretched to a resting tension of 0.2g, and washed with fresh Krebs' buffer at 15-min intervals during a 60-min equilibration period. After equilibration, trachea were challenged with either ovalbumin (10 mg ml 21 ) or compound 48/80. At the end of each experiment, all trachea were maximally contracted with carbachol (1 mM). All results are expressed as a percentage of maximum contraction. Hindpaw swelling and extravasation. Adult male mice up to 8 months of age were anaesthetized with an intraperitoneal (i.p.) injection of 50 mg kg 21 pentobarbital (Sigma). Fifteen minutes after induction of anaesthesia, mice were injected intravenously (i.v.) with 50 ml of 12.5 mg ml 21 Evans blue (Sigma) in saline. Five minutes later, 5 ml of the test substance (or 7 ml of anti-IgE) was administered by intraplantar injection in one paw and saline was administered in the other paw. Paw thickness was measured by callipers immediately after injection. Fifteen minutes later (30 min after anti-IgE), paw thickness was measured again and mice were killed by decapitation. Paw tissue was collected, dried for 24 h at 50 uC, and weighed. Evans blue was extracted by a 24 h incubation in formamide at 50 uC, and the OD was read at 620 nm using a spectrophotometer. For studies using ketotifen, mice were injected i.p. with 25 ml of a 10 mg ml 21 solution of ketotifen at the same time as pentobarbital. Systemic anaphylaxis assay. To minimize stress, animals were transported to the procedure area the day before injections. Adult male and female mice up to 8 months of age (25 to 35 g) were given an i.p. injection of 80 mg propranolol in saline (2 mg ml 21 ) immediately after removal from their cages, and then placed back in their cages for 30 min before intravenous injections. The intravenous injections were performed on one mouse at a time. For each injection, a mouse was placed in a transport box and brought to a room with no other mice, to minimize stress from vocalizations during injection. The mouse was then placed in a restrainer, and the injection was performed within 4 min of restraint because we observed that longer restraint times affected body core temperature independent from the injection. Tail veins were dilated by repeated wiping of tail with a tissue soaked in 100% ethanol, followed by injection of ciprofloxacin in a 0.25 ml Hamilton syringe fit with a 30.5-gauge needle (BD Biosciences). The injection was determined to be successful only when all of the criteria were met: blood appeared in the syringe after needle insertion, all tail veins were visible after injection, and the mouse bled slightly from the injection site after needle withdrawal. The injection site was swabbed until blood stopped flowing, the mouse was placed in a separate cage from its housing cage, one mouse per cage, and returned to the room it was brought from. At least one wild-type and one mutant mouse were used for each experimental session. Body core temperature was measured with a rectal thermometer. Mouse peritoneal mast cell histamine release assay. Mast cells were purified as described earlier and allowed to recover for 2 h in DMEM with 10% FBS and 25 ng ml 21 mouse stem cell factor in a 37 uC incubator with 5% CO 2 . Cells were . Substances were perfused from the 30 to 90 s time period, except for ciprofloxacin, which was perfused between the 30 and 60 s time periods to minimize exposure to the low pH solutions it was dissolved in. Insulin was used as a negative control. c, Table of halfmaximum effective concentration (EC 50 ) values of basic secretagogues and drugs associated with pseudo-allergic reactions to activate Mrgprb2-and MRGPRX2-expressing HEK293 cells. The EC 50 values were determined from dose-response studies, which were repeated three times. Data are expressed as mean 6 s.e.m.
LETTER RESEARCH

RESEARCH LETTER
